/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
or 97.0 percent of which profit attributable to the equity holder of the Company was 14.8 million baht. The weaker net profit was mainly due to substantial increase in fuel costs and excise tax on fuel
Acquisition of Assets of DOD Biotech Public Company Limited regarding the Acquisition of Land and Establishment of Subsidiary, which is Class 2 Transaction (Schedule 1) DOD Biotech Public Company Limited ( the
down 70kt or 17% year on year. On the positive side EBITDA per tonne increased 1% and as fuel is expected to reduce in 2020 the trend is encouraging. On the costs side SG&A decreased by -5% as a focus on
employee incentive programs. On the variable cost side fuel costs were higher than in the same period last year and also in fixed costs related to production maintenance cost increased due to the earlier
sales and service for the period ended 31 March 2022 and 2021 are presented below: Q1-2021 Q1-2022 Cost of sales and service THB Mn THB Mn THB Mn % Fuel materials cost 536.5 808.1 271.6 50.6% Depreciation
Corporation PCL. This amalgamation in accounting aspect has to be a sell of existing subsidiary, and then invest in the new bio-fuel company instead (KSL’s new associated company). As a result, the Company
Yield (2) Baht per Passenger - Kilometers 4.79 4.91 Revenue ASK (RASK) Baht per Available Seat - Kilometers 3.95 3.74 Cost per ASK (CASK) 3.30 3.36 Cost per ASK excluding fuel cost 2.70 2.70 RASK – CASK
- Kilometers 4.79 4.91 Revenue ASK (RASK) Baht per Available Seat - Kilometers 3.95 3.74 Cost per ASK (CASK) 3.43 3.36 Cost per ASK excluding fuel cost 2.76 2.70 RASK – CASK 0.52 0.38 Remark (1) These figures